510(k) device
XO1 Knee Balancing System
Xpandortho, Inc. · Intraoperative Orthopedic Joint Assessment Aid (ONN, Class II) · First FDA decision Apr 25, 2017, newest Apr 25, 2017Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "XO1"
MAUDE reports
0
Brand "XO1", since 2015
PubMed studies
21
Mentioning "XO1"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing XO1 Knee Balancing System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K162237 · Decided Apr 25, 2017 · 259 days after receipt
Device type: Intraoperative Orthopedic Joint Assessment Aid (ONN) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "XO1", any status and sponsor, newest update first.
No registered device study names "XO1".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "XO1", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code ONN
7 reports: 7 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "XO1"[tiab]. The summary above synthesizes these.
- Dielectrophoresis: an assessment of its potential to aid the research and practice of drug discovery and delivery.
Pethig R · Adv Drug Deliv Rev · 2013Review
- A resistance locus in the American heirloom rice variety Carolina Gold Select is triggered by TAL effectors with diverse predicted targets and is effective against African strains of Xanthomonas oryzae pv. oryzicola.
Triplett LR, Cohen SP, Heffelfinger C, et al. · Plant J · 2016Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural
- An apparent threshold dose response in ferrous xylenol-orange gel dosimeters when scanned with a yellow light source.
Babic S, Battista J, Jordan K · Phys Med Biol · 2008Research Support, Non-U.S. Gov't
- Dielectrophoretic characterization of antibiotic-treated Mycobacterium tuberculosis complex cells.
Inoue S, Lee HB, Becker AL, et al. · Anal Bioanal Chem · 2015
- Xa1 Allelic R Genes Activate Rice Blight Resistance Suppressed by Interfering TAL Effectors.
Ji C, Ji Z, Liu B, et al. · Plant Commun · 2020Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- Suppression of Xo1-Mediated Disease Resistance in Rice by a Truncated, Non-DNA-Binding TAL Effector of Xanthomonas oryzae.
Read AC, Rinaldi FC, Hutin M, et al. · Front Plant Sci · 2016
- Cloning of the Rice Xo1 Resistance Gene and Interaction of the Xo1 Protein with the Defense-Suppressing Xanthomonas Effector Tal2h.
Read AC, Hutin M, Moscou MJ, et al. · Mol Plant Microbe Interact · 2020
- Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming.
Chen J, Wang YK, Gao Y, et al. · Biomed Pharmacother · 2020
- Exosomes isolated from human cardiosphere-derived cells attenuate pressure overload-induced right ventricular dysfunction.
Bittle GJ, Morales D, Pietris N, et al. · J Thorac Cardiovasc Surg · 2021Research Support, N.I.H., Extramural
- Overall Water Splitting on the Transition-Metal Oxynitride Photocatalyst LaMg1/3Ta2/3O2N over a Large Portion of the Visible-Light Spectrum.
Pan C, Takata T, Domen K · Chemistry · 2016Research Support, Non-U.S. Gov't
- Effector Mimics and Integrated Decoys, the Never-Ending Arms Race between Rice and Xanthomonas oryzae.
Zuluaga P, Szurek B, Koebnik R, et al. · Front Plant Sci · 2017Review
- Effect of Blueberry Anthocyanins Malvidin and Glycosides on the Antioxidant Properties in Endothelial Cells.
Huang W, Zhu Y, Li C, et al. · Oxid Med Cell Longev · 2016Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code ONN.
- VERASENSE for Exactech Equinoxe Size 38 mmOrthosensor, Inc. · 510(k) 2020
- Lantern Knee Navigation Unit (406000-03)Orthalign, Inc. · 510(k) 2026
- Quadsense (Quadsense and Quadsense Pro)Eventum Orthopaedics, Ltd. · 510(k) 2025
- Orthosensor Knee Balancer, Verasense Knee SystemOrthosensor, Inc. · 510(k) 2013
- Packaged Assembly, Reusable Navigation UnitOrthalign, Inc. · 510(k) 2026
- TrueBalance Surgical SystemThese Three Medical, LLC · 510(k) 2022
- Elibra Soft-Tissue Force SensorKamm & Associates · 510(k) 2014
- Elibra Uni Soft-Tissue Force Sensor, Model 61-XXXX(5 Models, Different SizesSynvasive Technology, Inc. · 510(k) 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.